Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039606 | 0.93 | PRCP (0.55) | PRCPHCRTR1HCRTR2CPT2CPT1A | |
| SCHEMBL563467 | 0.93 | PRCP (0.54) | PRCPHCRTR1HCRTR2KCNH2 | |
| SCHEMBL563468 | 0.93 | PRCP (0.54) | PRCPHCRTR1HCRTR2KCNH2 | |
| SCHEMBL564422 | 0.90 | PRCP (0.52) | PRCPHCRTR1HCRTR2CYP3A4CYP2C9 | |
| SCHEMBL564421 | 0.90 | PRCP (0.52) | PRCPHCRTR1HCRTR2CYP3A4CYP2C9 | |
| SCHEMBL10039617 | 0.87 | HCRTR1 (0.48) | PRCPHCRTR1HCRTR2CYP3A4CYP2C9 | |
| SCHEMBL10039592 | 0.86 | PRCP (0.59) | PRCPHCRTR1HCRTR2CPT2CPT1A | |
| SCHEMBL10039598 | 0.86 | PRCP (0.48) | PRCPHCRTR1HCRTR2CYP3A4CYP2C9 | |
| SCHEMBL10039603 | 0.85 | PRCP (0.48) | PRCPHCRTR1HCRTR2CPT1ACYP3A4 | |
| SCHEMBL10039602 | 0.84 | PRCP (0.56) | PRCPHCRTR1HCRTR2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436036-B2 | Diaryl ethers | JANSSEN R&D IRELAND (IE) | 2013-05-07 | — | — | US | disclosed |
| US-20120034678-A1 | Diaryl Ethers | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-09 | — | — | US | disclosed |
| US-20120034678-A1 | Diaryl Ethers | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122162-A1 | DIARYL ETHERS | TIBOTEC PHARMACEUTICALS (IE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034678-A1 | Diaryl Ethers | SLC10A1, CYP2F1, UGT1A1 | PRCP 1514/4885HCRTR1 4096/4885HCRTR2 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.